Business news from Ukraine

BIOPHARMA LAUNCHES STATE-OF-THE-ART $75 MILLION PLASMA FRACTIONATION PLANT IN UKRAINE

Biopharma, a top-ten pharmaceutical producer in Ukraine specializing in plasma-based, recombinant and other drugs, has officially opened its innovative fractionator in Bila Tserkva (Kyiv region), the only biopharmaceutical plant of its kind in Eastern Europe and the near region. There are no plasma fractionation plants in any neighboring countries – the closest are in Austria, South Africa and China.  This unique plasma fractionation technology enables the plasma component of human blood to be processed to extract life-saving drugs, requires advanced research and development, GMP-certified equipment and facilities, and investments exceeding $75 million.

“September 20 will become a new page in the modern scientific and industrial history of Ukraine, as not just a new production facility was launched, – a new science-based industry was launched based on high technologies. This puts Ukraine on par with countries such as the USA, Austria, Germany and allows Ukraine to enter the world market with medicines, the production of which requires its own R&D base, high culture of production, development of donor infrastructure according with the highest standards. Today, Ukraine has proved that it is capable of that!” – Kostyantyn Efymenko, president of Biopharma group of companies emphasized.

Biopharma’s new facility is the first and only plasma fractionation plant in Ukraine that will have the capacity to process up to one million liters of plasma per year. This will fully meet the country’s internal needs for plasma-based drugs, which is an important element of national security of Ukraine. By replacing imported drugs with high-quality Ukraine-processed plasma products, Biopharma estimates that the country will save up to $100 million per year. In addition, the launch of the new plant will allow Biopharma to double the significant amount of local and state taxes paid, making the сompany the largest taxpayer in Bila Tserkva, contributing more than all local businesses combined.

“We believe in the high potential of Ukraine and its pharmaceutical industry in particular. Together with our partners, we haven’t stopped investing and, in the difficult times of the new history, continued to systematically develop the company. I am proud that Biopharma has mastered the advanced and very sophisticated technology that is available in few countries in the world. This is why we’ll be able to compete not only on the local market, but also on the global one”, – Vasyl Khmelnytsky, founder of UFuture, said.

Lenna Koszarny, Founding Partner and CEO, Horizon Capital, added: “Horizon Capital’s EEGF II Fund and Dutch development finance bank FMO invested in Biopharma in 2012 to address the serious issue of 120 tons of plasma thrown out each year not processed into life-saving drugs, because a plant like this did not exist in Ukraine.  We were attracted by the vision of operating shareholder Kostyantyn Efymenko and through his leadership and commitment as well as the dedication of the Company’s committed shareholders and excellent management team, this vision has become a reality.  In June 2015, Biopharma launched a state-of-the art greenfield non-plasma plant, and today, we are proud to launch the most modern plasma fractionation plant in Central and Eastern Europe and contribute to Biopharma’s success”.

The new plant is equipped with modern machinery produced by the world-known manufacturers such as Stilmas, Olsa, GEA Westfalia, General Electric healthcare, Pall, Steriline. It has three production lines for albumin, immunoglobulin and factor VIII drugs that are critical for victims of severe injuries and burns, for people fighting cancer, hemophilia, for pregnant women and other patients.

Linda Broekhuizen, Chief Investment Officer of FMO, says: “FMO congratulates the shareholders and management of Biopharma with the launch of the new fractionator plant. A great milestone that underlines the company’s entrepreneurial drive and commitment to investing in growth, even though the Ukrainian economy has undergone tremendous challenges. This state-of-the-art facility provides jobs and reduces dependence from imports, both healthy ingredients to further economic growth.”

The opening ceremony was attended by more than 1,000 guests, including government representatives, medical professionals, the business community from Ukraine and from over 20 countries.

Contact for the media: Tetyana Shvets, +38067 604 3 555.

ADDITIONAL INFORMATION

Biopharma is a Ukrainian immunobiological pharmaceutical company that develops and manufactures drugs based on human blood, recombinant drugs, probiotics based on spore-forming bacteria and traditional drugs. The company produces about 20 million packages of drugs per year. The number of employees – more than 500 people. The company exports drugs to 36 countries. At least 4 times a year, Biopharma is a subject to quality review by foreign and Ukrainian auditors.

UFuture is a holding company of Ukrainian entrepreneur Vasyl Khmelnytsky that integrates his business and impact-investment projects.  The Company has a diversified portfolio of assets in real estate, industry, infrastructure, renewable energy, pharmaceuticals, and IT.  As of today, UFuture’s assets are estimated at $550 million with total capitalization of the businesses invested in exceeding $1 billion.

Horizon Capital is the leading private equity firm in Ukraine, backed by over 40 institutional investors in four funds with over $850 million in assets under management. Its Ukraine-focused funds have invested over $700 million in 140 companies employing over 52,000 people in Ukraine and neighboring countries.  Horizon Capital is a value-added investor, backing visionary entrepreneurs leading transformational businesses in Ukraine and the near region.

FMO is the Dutch entrepreneurial development bank. As a leading impact investor, FMO supports sustainable private sector growth in developing countries and emerging markets by investing in ambitious projects and entrepreneurs. FMO believes that a strong private sector leads to economic and social development and has a close to 50-year proven track-record of empowering people to employ their skills and improve their quality of life. FMO focuses on three sectors that have high development impact: financial institutions, energy, and agribusiness, food & water. With a committed portfolio of EUR 9.7 billion spanning over 85 countries, FMO is one of the larger bilateral private sector developments banks globally.

,

BLOOD PREPARATIONS MANUFACTURER BIOPHARMA TO OFFICIALLY OPEN FRACTIONATOR PLANT IN KYIV REGION

The blood preparations manufacturer, Biopharma, at the end of September will officially open a fractionator plant in Bila Tserkva (Kyiv region).
As the company told Interfax-Ukraine, the construction and commissioning work lasted about four years. In total, the company invested more than $75 million in the construction of the plant.
The plant has installed equipment from global manufacturers in the industry: Stilmas, Olsa, GEA Westfalia, General Electric healthcare, Pall, and Steriline.
“This is the only this kind of plant in Eastern Europe. Our competitors are in Austria, South Africa and China. None of the neighboring countries has such production,” the company said.
For the official opening of the production Biopharma will hold an international conference entitled “Topical Issues of Industrial Production of Blood Products” with the participation of representatives of scientific, medical and regulatory institutions in the field of transfusion from more than 20 countries.
As reported, the plant will have three lines for the production of albumin, immunoglobulin, and factor VIII. The processing capacity ranges from 250,000 to one million liters of plasma per year. Biopharma planned to put it into operation at the end of 2018.
Biopharma immunobiological pharmaceutical company is among the ten largest Ukrainian manufacturers of drugs. It produces more than 20 immunobiological preparations from donated blood plasma, preparations obtained by recombinant DNA technology and probiotics.

BIOPHARMA STARTS COMMISSIONING WORK AT NEW PLANT IN BILA TSERKVA

Biopharma, a manufacturer of products from human donor plasma, has begun commissioning work at a new fractionator plant, which is being built in Bila Tserkva (Kyiv region).
“Biopharma has started commissioning work at the new plant,” Kostiantyn Yefymenko, the head of the board of directors of the Biopharma group of companies, said on his Facebook page.
According to him, at present, the plant has already launched warehouses for raw materials and finished products, while systems for water supply, chilled water, water for injection, steam, diethylene glycol, compressed air, purified air, neutralization of waste water are being tested.
As reported, investment in the construction of a new plant fractionator of blood plasma amounted to about $50 million. The plant will have three lines for the production of albumin, immunoglobulin, and factor VIII. The processing capacity ranges from 250,000 to one million liters of plasma per year. Biopharma planned to put it into operation at the end of 2018.
Biopharma immunobiological pharmaceutical company is among the ten largest Ukrainian manufacturers of drugs. It produces more than 20 immunobiological preparations from donated blood plasma, preparations obtained by recombinant DNA technology and probiotics.

, ,

CABINET OF MINISTERS PERMITS BIOPHARMA TO EXPORT DONOR BLOOD PREPARATIONS FOR INDEFINITE PERIOD OF TIME

The Cabinet of Ministers of Ukraine has permitted the manufacturer of blood-derived products Biopharma Plasma LLC (Kyiv region) to sell donor blood preparations outside of the country for the indefinite period of time. The government approved the resolution at a meeting on Tuesday. The implementation of the resolution will contribute to an increase in the volume of production of medicines and the expansion of the export potential of Ukraine.
As reported, at the end of 2017, the Cabinet of Ministers issued Biopharma Plasma a license to export 32 names of medicines and medical products outside Ukraine in 2018.
Biopharma is among the ten largest Ukrainian drug manufactures. Biopharma produces more than 20 immunobiological preparations of blood, as well as drugs obtained by recombinant DNA technology and probiotics.
According to the National Commission for Securities and the Stock Market, shares in Biopharma Plasma belong to Niobera Investments Limited (Cyprus). The holder of a majority stake and the beneficiary (the holder) of the majority stake of the shareholder Niobera Investments Limited is Kostiantyn Yefymenko. Another beneficiary of Niobera Investments Limited is Vasyl Khmelnytsky.

, , , ,

UNIT.CITY, BIOPHARMA AND OTHER COMPANIES ENTER EBA

The European Business Association (EBA) in September got 15 new members, including Ukrlandfarming, one of the largest agricultural holdings in terms of land bank, the UNIT.City innovative park, Biopharma pharmaceutical plant LLC and ADD (Apteka Dobroho Dnia) pharmacy chain.
According to the EBA, among its new members are also Aakon Grain Ukraine LLC with an elevator of 10,000 tonnes, providing agricultural machinery leasing services, Brovary Aluminum Plant from ALUMETA Group, and Art Nation of movie maker Eduard Akhramovych, working in the sphere of marketing.
Its new members also became Audit Consult Group LLC, the creators of premises for entrepreneurs Business Interiors LLC, a real estate company from Benish Group GmbH, Edwin Steel Corporation LLC and Goodgrainoil, selling grain and oilseeds.
According to the release, in addition, EBA members became Perenio, whose parent company Perenio IoT has its headquarters in the Czech Republic, Rent-a-car Ukraine LLC, an official representative of Europcar in Ukraine, and Skyrora UA, a subsidiary of British-based Skyrora Limited of Volodymyr Levykin.
The EBA told Interfax-Ukraine the total number of the association members reached 979 companies.

, ,

BIOPHARMA TO BOOST EXPORTS BY 60% INCLUDING NEW COUNTRIES (BANGLADESH AND COLOMBIA)

Kyiv-based producer of blood-derived products Biopharma is to boost exports by 60% in August 2018 year-over-year, to UAH 130 million. Exports in August will be 40% higher than the monthly average indicator during the year, the company’s press service said. In August 2018, the company will ship, in addition to Ukraine, to markets of 10 countries, including Belarus, Kazakhstan, India, Colombia, Uzbekistan, Azerbaijan, Middle East countries, as well as to Slovakia, Mongolia, and Bangladesh. It should be noted that Biopharma’s products will be delivered to Bangladesh and Colombia for the first time. The company’s plans include the expansion of its presence in the European markets.
Biopharma immunobiological pharmaceutical company is one of the ten largest Ukrainian producers of medicines. It produces more than 20 immunobiological preparations from donated blood, preparations obtained with the use of recombinant DNA technology and probiotics.
In 2015, the company invested $3.5 million in the reconstruction of Sumy region’s blood center, which currently accounts for 98.2% of donated blood in the region.
Biopharma plans to launch a plasma fractionation plant in 2018. The Biopharma Group of Companies includes LLC Biopharma Invest, LLC Biopharma Plasma Invest, LLC Biopharma Plasma, and LLC Fractionation Plant FZ Biopharma.

, , ,